Baker Bros. Advisors MPLT Position
Active3-Fund ConvergenceBaker Bros. Advisors initiated a new position in MapLight Therapeutics, Inc. (MPLT) in Q4 2025, holding $6.4M worth of shares across 364,705 shares.
MPLT is a convergence signal: 3 specialist biotech funds hold this stock, suggesting high institutional conviction.
There is an upcoming Phase 2 readout for Placebo in 139 days (Aug 31, 2026), making the timing of Baker Bros.'s position particularly relevant.
About MapLight Therapeutics, Inc.
MapLight Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company for patients suffering from debilitating central nervous system disorders. The company's products include ML-007C-MA, a fixed-dose combination of an M 1 /M 4 muscarinic agonist for the treatment of schizophrenia and Alzheimer's disease psychosis; ML-004 for the treatment of social communication deficit and/or irritability in autism spectrum disorder; ML-021 for the treatment of motor deficits in Parkinson's disease; and ML-009, a G-protein-coupled receptor 52 positive allosteric modulator for the treatment of hyperactivity, impulsivity and agitation-related disorders. The company also develops platform identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation. MapLight Therapeutics, Inc. was formerly known as Alvarado Therapeutics, Inc. and changed its name to MapLight Therapeutics, Inc. in August 2019. MapLight Therapeutics, Inc. was incorporated in 2018 and is based in Redwood City, California. MapLight Therapeutics, Inc operates as a subsidiary of Catalyst4, Inc.
Full company profile →Short Interest
3.1%
9.3 days to cover
Frequently Asked Questions
Does Baker Bros. Advisors own MPLT?
Yes. As of Q4 2025, Baker Bros. Advisors holds 364,705 shares of MapLight Therapeutics, Inc. (MPLT) valued at $6.4M. This data comes from their SEC 13F filing.
How many hedge funds own MPLT?
3 specialist biotech hedge funds currently hold MPLT, including Perceptive Advisors, OrbiMed Advisors. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Baker Bros. Advisors first buy MPLT?
Baker Bros. Advisors's position in MPLT was first reported in Q4 2025. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Baker Bros. Advisors's MPLT position increasing or decreasing?
Baker Bros. Advisors initiated a new position in MPLT in the most recent quarter. This is their first reported holding.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
MPLTCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Baker Bros. AdvisorsPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →